5 Key Takeaways
-
1
In the phase 2b/3 BRUNELLO trial, both remigromig doses met the primary endpoint of noninferiority to monthly ranibizumab for mean BCVA change at 1 year.
-
2
Mean BCVA gains at 1 year were 9.1 letters with remigromig 0.5 mg, 8.7 letters with 0.8 mg, and 11.8 letters with ranibizumab.
-
3
No secondary endpoint showed superiority to ranibizumab, and treatment-group differences in BCVA were within the prespecified noninferiority margin.
-
4
PDR-related adverse events occurred in 6.7% and 6.1% of patients receiving remigromig 0.5 mg and 0.8 mg, respectively, versus 0.9% with ranibizumab.
-
5
Adverse event–related treatment discontinuations occurred in 4.9% and 4.5% of patients receiving remigromig 0.5 mg and 0.8 mg, respectively, versus 0.9% with ranibizumab.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.